







an Open Access Journal by MDPI

Advances in Inherited Breast and Ovarian Cancer and Its Imaging

Guest Editors:

Prof. Dr. Gareth Evans

Division of Evolution & Genomic Sciences, the University of Manchester, Manchester, United Kingdom

Dr. Emma Woodward

Manchester University NHS Foundation Trust, Manchester, United Kingdom

Prof. Dr. Judy Garber

Dana-Farber Cancer Institute and Medicine at Harvard Medical School, MA 02115, USA

Deadline for manuscript submissions:

closed (15 July 2023)

Message from the Guest Editors

It is our pleasure to announce the launch of a new Special Issue in *Cancers* on the topic of "Advances in Inherited Breast and Ovarian Cancer and Its Imaging". As the title suggests, we are interested in articles that reflect the sea change in inherited breast and ovarian cancer, specifically in the last 2–3 years. Some of the topics of interest include:

- 1. Emergence of genes now established as causative in both cancers, e.g., RAD51C and RAD51D;
- Contribution of genes other than BRCA1 and BRCA2;
- 3. Emergence of clinical utility of polygenic risk scores;
- 4. Emergence of new preventive agents such as antiprogestins and RANKLi;
- 5. Updates on MRI screening;
- 6. Updates on ovarian screening.

We look forward to receiving your submissions.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us